Genomic Profiling in Luminal Breast Cancer
- 1 December 2013
- journal article
- review article
- Published by S. Karger AG in Breast Care
- Vol. 8 (6), 414-422
- https://doi.org/10.1159/000357535
Abstract
SummaryThe developments in gene expression analysis have made it possible to sub-classify hormone receptor-positive (luminal) breast cancer in different prognostic subgroups. This sub-classification is currently used in clinical routine as prognostic signature (e.g. 21-gene Onoctype DX®, 70-gene Mammaprint®). As yet, the optimal method for sub-classification has not been defined. Moreover, there is no evidence from prospective trials. This review explores widely used genomic signatures in luminal breast cancer, making a critical appraisal of evidence from retrospective/prospective trials. It is based on systematic literature search performed using Medline (accessed September 2013) and abstracts presented at the Annual Meeting of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium.Keywords
This publication has 73 references indexed in Scilit:
- PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancerBreast Cancer Research and Treatment, 2013
- A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studyInternational Journal of Cancer, 2013
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)Breast Cancer Research and Treatment, 2011
- Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trialBritish Journal of Cancer, 2011
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002